Special Issue "MET in Cancer"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (31 May 2014)
Prof. Dr. Livio Trusolino
Laboratory of Molecular Pharmacology, Institute for Cancer Research and Treatment (IRCC), University of Torino Medical School, 10060 Candiolo, Torino, Italy
Website | E-Mail
Fax: +39 011 993 3225
Interests: MET oncogene; tyrosine kinase signalling; anti-cancer targeted therapies; genetic determinants of response and resistance; preclinical animal models; molecular pathology of colorectal cancer
This special issue invites investigators to contribute original research reports as well as review articles that describe studies on the MET oncogene.
The MET oncogene encodes the tyrosine kinase receptor for hepatocyte growth factor (HGF). MET signaling triggers pro-mitogenic and anti-apoptotic pathways that sustain tumor growth and progression in several cancer settings. Accordingly, relentless activation of MET due to protein overexpression or gain-of-function genetic abnormalities is a hallmark of several malignancies and correlates with aggressive disease. Recent drug development efforts have led to the characterization of several MET-blocking reagents, including monoclonal antibodies and small molecule inhibitors, some of which have entered clinical trials. The challenge now is to leverage what is known about MET genetics, signals and functions for molecularly-based stratification of patients potentially responsive to MET inhibition.
Tentative topics include, but are not limited to:
- Insights into the signaling mechanisms of MET activity: receptor recycling, degradation, and signal compartmentalization.
- Predictive biomarkers of response and resistance to MET inhibitors
- Tumor settings that might benefit from rational treatment with MET inhibitors
- MET activation and resistance to targeted therapies
- MET in the tumor microenvironment
Prof. Dr. Livio Trusolino
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- cell migration and invasion
- prognostic and predictive biomarkers
- MET inhibitors
- MET-dependent signal transduction pathways
- oncogene addiction
- tumor-stroma interactions